



Atty. Dkt. No. 017371-0109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nicholas MANOLIOS
Title: T CELL ANTIGEN RECEPTOR PEPTIDES
Appl. No.: 09/202,305
Filing Date: 03/22/1999
Examiner: Anish Gupta
Art Unit: 1654

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.97(e)(1) that each item of information contained in this supplemental information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

9/25/04

By




For

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

key NOY3445

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO/SB/08

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: September 29, 2004

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/202,305
Filing Date	03/22/1999
First Named Inventor	Nicholas MANOLIOS
Group Art Unit	1654
Examiner Name	Anish Gupta
Attorney Docket Number	017371-0109

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1		EP 0 443 404		The Medical College of Pennsylvania	8/28/1991		
	A2		WO 95/26980		Immologic Pharmaceutical Corp.	10/12/1995		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A3	International Search Report	
	A4	Vijay K. KUCHROO et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Repertoire", The Journal of Immunology, The Williams and Wilkins Co., Baltimore, US, vol. 153, no. 7, October 1, 1994, pp. 3326-3336.	
	A5	S.C. JAMESON et al., "Clone-Specific T Cell Receptor Antagonists of Major Histocompatibility Complex Class I-Restricted Cytotoxic T Cells", Journal of Experimental Medicine, Tokyo, Japan, vol. 177, no. 6, June 1, 1993, pp. 1541-1550.	
	A6	K.A. HOGQUIST et al., "T Cell Receptor Antagonist Peptides Induce Positive Selection", Cell, Cell Press, Cambridge, NA, US, vol. 76, no. 1, January 14, 1994.	
	A7	N. KARIN et al., "Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Factor Alpha Production", Journal of Experimental Medicine, Tokyo, JP, vol. 180, no. 6, December 1, 1994, pp. 2227-2237.	
	A8	M. T. DE MAGISTRIS et al., "Antigen Analog-Major Histocompatibility Complexes Act as Antagonists of the T Cell Receptor", CELL, vol. 68, no. 4, February 21, 1992, pp. 625-634.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.